BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
Clinical data and patient-reported outcomes across extensive clinical development program for zanubrutinib (BRUKINSA®) reinforce its potential across B-cell malignancies Long-term...










